CaPtivate Pharmaceuticals
Small biotechnology company developing a calcium phosphate nanoparticle adjuvant and delivery platform for human and veterinary vaccines. Activities described include preclinical development across multiple antigens, formulation for parenteral and mucosal administration (including intranasal dry-powder formats), pilot-scale GMP manufacturing of inorganic nanoparticles, and partnering/licensing or material transfer for external vaccine programs.
Industries
Nr. of Employees
small (1-50)
CaPtivate Pharmaceuticals
Doylestown, Pennsylvania, United States, North America
Products
Calcium phosphate nanoparticle adjuvant platform
A biodegradable calcium phosphate nanoparticle platform used as a vaccine adjuvant and delivery system designed to enhance humoral, cellular, and mucosal immune responses and enable dry-powder formulations.
Nasal influenza vaccine formulations (preclinical)
Preclinical development of inactivated influenza virus vaccines formulated for intranasal delivery, including powder formulations and studies against seasonal and pandemic strains.
Calcium phosphate nanoparticle adjuvant platform
A biodegradable calcium phosphate nanoparticle platform used as a vaccine adjuvant and delivery system designed to enhance humoral, cellular, and mucosal immune responses and enable dry-powder formulations.
Nasal influenza vaccine formulations (preclinical)
Preclinical development of inactivated influenza virus vaccines formulated for intranasal delivery, including powder formulations and studies against seasonal and pandemic strains.
Services
Nanoparticle formulation and evaluation services
Formulation of vaccine antigens with calcium phosphate nanoparticles for parenteral or mucosal administration and provision of material for partner evaluation under MTAs or collaborative agreements.
Nanoparticle formulation and evaluation services
Formulation of vaccine antigens with calcium phosphate nanoparticles for parenteral or mucosal administration and provision of material for partner evaluation under MTAs or collaborative agreements.
Expertise Areas
- Vaccine adjuvant development
- Nanoparticle-based antigen delivery
- Mucosal (intranasal) vaccine formulation
- Thermostable dry-powder vaccine development
Key Technologies
- Calcium phosphate nanoparticle platform
- Mucosal (intranasal) vaccine delivery
- Thermostable dry powder (freeze-dried) formulations
- Antigen adsorption to inorganic nanoparticles